OVID logo

OVID
Ovid Therapeutics Inc

6,180
Mkt Cap
$507M
Volume
328,896.00
52W High
$3.11
52W Low
$0.2701
PE Ratio
-10.78
OVID Fundamentals
Price
$2.94
Prev Close
$2.83
Open
$2.83
50D MA
$2.36
Beta
1.08
Avg. Volume
2.99M
EPS (Annual)
-$0.2362
P/B
2.82
Rev/Employee
$315,304.35
$63.97
Loading...
Loading...
News
all
press releases
Ovid Therapeutics (OVID) to Release Earnings on Tuesday
Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,957,013 shares, a decline of 25.5% from the March 31st total of 9,337,824 shares. Based on an average trading volume of...
MarketBeat·7d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One research...
MarketBeat·16d ago
News Placeholder
Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush
Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of Ovid Therapeutics in a report on Wednesday...
MarketBeat·21d ago
News Placeholder
Short Interest in Ovid Therapeutics (NASDAQ:OVID) Increases By 71.2%
Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 9,337,824 shares, an increase...
MarketBeat·23d ago
News Placeholder
HC Wainwright Issues Positive Forecast for OVID Earnings
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Ovid Therapeutics in a research note issued on...
MarketBeat·23d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Price Target Raised to $4.00
HC Wainwright boosted their price objective on shares of Ovid Therapeutics from $2.00 to $4.00 and gave the company a "buy" rating in a research report on Thursday...
MarketBeat·27d ago
News Placeholder
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at BTIG Research
BTIG Research reiterated a "buy" rating and issued a $4.00 price objective on shares of Ovid Therapeutics in a report on Thursday...
MarketBeat·1mo ago
News Placeholder
Lifesci Capital Has Negative Estimate for OVID Q1 Earnings
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Analysts at Lifesci Capital dropped their Q1 2026 earnings per share estimates for Ovid Therapeutics in a research note issued to investors on Tuesday...
MarketBeat·1mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports...
MarketBeat·1mo ago
<
1
2
...
>

Latest OVID News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.